﻿{"id":16441,"date":"2025-10-21T10:29:57","date_gmt":"2025-10-21T03:29:57","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=16441"},"modified":"2025-10-21T10:29:57","modified_gmt":"2025-10-21T03:29:57","slug":"lamotrigine","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/lamotrigine\/","title":{"rendered":"Lamotrigine"},"content":{"rendered":"<p>(Ph. Eur. monograph 1756)<\/p>\n<p>C<sub>9<\/sub>H<sub>7<\/sub>Cl<sub>2<\/sub>N<sub>5\u00a0<\/sub> \u00a0 \u00a0 \u00a0256.1\u00a0 \u00a0 \u00a0 \u00a084057-84-1<\/p>\n<p><strong>Action and use<\/strong><\/p>\n<p>Antiepileptic.<\/p>\n<p><strong>Preparations<\/strong><\/p>\n<p>Lamotrigine Dispersible Tablets<\/p>\n<p>Lamotrigine Tablets<\/p>\n<h2>DEFINITION<\/h2>\n<p>6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine.<\/p>\n<h3>Content<\/h3>\n<p>99.0 per cent to 101.0 per cent (dried substance).<\/p>\n<h2>CHARACTERS<\/h2>\n<h3>Appearance<\/h3>\n<p>White or almost white powder.<\/p>\n<p>Solubility<\/p>\n<p>Very slightly soluble in water, slightly soluble in anhydrous ethanol.<\/p>\n<h2>IDENTIFICATION<\/h2>\n<p>Infrared absorption spectrophotometry (2.2.24).<\/p>\n<p>Comparison: lamotrigine CRS.<\/p>\n<h2>TESTS<\/h2>\n<h3>Related substances<\/h3>\n<p>Liquid chromatography (2.2.29).<\/p>\n<p>Test solution: Dissolve 20 mg of the substance to be examined in 5 mL of methanol R and dilute to 100.0 mL with a 10.3 g\/L solution of hydrochloric acid R.<\/p>\n<p>Reference solution (a): Dissolve 5 mg of lamotrigine for system suitability CRS (containing impurity G) in 2.5 mL of methanol R and dilute to 25.0 mL with a 10.3 g\/L solution of hydrochloric acid R.<\/p>\n<p>Reference solution (b): Dilute 1.0 mL of the test solution to 100.0 mL with a 10.3 g\/L solution of hydrochloric acid R. Dilute 2.0 mL of this solution to 10.0 mL with a 10.3 g\/L solution of hydrochloric acid R.<\/p>\n<p>Reference solution (c): Dissolve 5.0 mg of lamotrigine impurity E CRS in a mixture of 0.25 mL of hydrochloric acid R and 45 mL of methanol R and dilute to 50.0 mL with methanol R. Dilute 5.0 mL of the solution to 100.0 mL with a 10.3 g\/L solution of hydrochloric acid R. To 4.0 mL of this solution add 5 mL of methanol R and dilute to 100.0 mL with a 10.3 g\/L solution of hydrochloric acid R.<\/p>\n<p>Reference solution (d): Dissolve 10 mg of lamotrigine for peak identification CRS (containing impurities A, E and F) in 2.5 mL of methanol R and dilute to 50.0 mL with a 10.3 g\/L solution of hydrochloric acid R.<\/p>\n<p>Blank solution: Mix 5 volumes of methanol R and 95 volumes of a 10.3 g\/L solution of hydrochloric acid R.<\/p>\n<p>Column:<\/p>\n<p>\u2014 size: l = 0.15 m, \u00d8 = 4.6 mm;<\/p>\n<p>\u2014 stationary phase: base-deactivated end-capped octadecylsilyl silica gel for chromatography R (5 \u03bcm);<\/p>\n<p>\u2014 temperature: 35 \u00b0C.<\/p>\n<p>Mobile phase:<\/p>\n<p>\u2014 mobile phase A: mix 1 volume of triethylamine R and 150 volumes of a 2.7 g\/L solution of potassium dihydrogen phosphate R; adjust to pH 2.0 with phosphoric acid R;<\/p>\n<p>\u2014 mobile phase B: acetonitrile R;<\/p>\n<table style=\"border-collapse: collapse; width: 100%; height: 85px;\">\n<tbody>\n<tr style=\"height: 43px;\">\n<td style=\"width: 33.3333%; height: 43px; text-align: center;\"><strong>Time<\/strong><br \/>\n<strong>(min)<\/strong><\/td>\n<td style=\"width: 33.3333%; height: 43px; text-align: center;\"><strong>Mobile phase A<\/strong><br \/>\n<strong>(per cent V\/V)<\/strong><\/td>\n<td style=\"width: 33.3333%; height: 43px; text-align: center;\"><strong>Mobile phase B<\/strong><br \/>\n<strong>(per cent V\/V)<\/strong><\/td>\n<\/tr>\n<tr style=\"height: 21px;\">\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">0 &#8211; 4<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">85<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">15<\/td>\n<\/tr>\n<tr style=\"height: 21px;\">\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">4 &#8211; 14<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">85 \u2192 20<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">15 \u2192 80<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Flow rate: 1.0 mL\/min.<\/p>\n<p>Detection: Spectrophotometer at 270 nm.<\/p>\n<p>Injection: 10 \u03bcL of the test solution, reference solutions (a), (b) and (d) and the blank solution.<\/p>\n<p>Identification of impurities: Use the chromatogram supplied with lamotrigine for peak identification CRS and the chromatogram obtained with reference solution (d) to identify the peaks due to impurities A, E and F; use the chromatogram supplied with lamotrigine for system suitability CRS and the chromatogram obtained with reference solution (a) to identify the peak due to impurity G.<\/p>\n<p>Relative retention: With reference to lamotrigine (retention time = about 7 min): impurity G = about 1.1; impurity A = about 1.3; impurity E = about 1.7; impurity F = about 1.8.<\/p>\n<p>System suitability: Reference solution (a):<\/p>\n<p>\u2014 peak-to-valley ratio: minimum 1.2, where Hp = height above the baseline due to impurity G and H<sub>v<\/sub> = height above the baseline of the lowest point of the curve separating this peak from the peak due to lamotrigine.<\/p>\n<p>Limits:<\/p>\n<p>\u2014 correction factor: for the calculation of content, multiply the peak area of impurity F by 1.3;<\/p>\n<p>\u2014 impurity F: not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.2 per cent);<\/p>\n<p>\u2014 impurities A, G: for each impurity, not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.1 per cent);<\/p>\n<p>\u2014 unspecified impurities: for each impurity, not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent);<\/p>\n<p>\u2014 total: not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.2 per cent);<\/p>\n<p>\u2014 disregard limit: 0.25 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent); disregard any peak due to impurity E.<\/p>\n<h3>Impurity E<\/h3>\n<p>Liquid chromatography (2.2.29) as described in the test for related substances with the following modifications.<\/p>\n<p>Mobile phase: acetonitrile for chromatography R, mobile phase A (35:65 V\/V).<\/p>\n<p>Detection: Spectrophotometer at 210 nm.<\/p>\n<p>Injection: Test solution and reference solutions (d) and (c).<\/p>\n<p>Run time: 10 min.<\/p>\n<p>Retention time: Impurity E = about 5.5 min; impurity F = about 8.5 min.<\/p>\n<p>System suitability: Reference solution (d):<\/p>\n<p>\u2014 the chromatogram obtained is similar to the chromatogram supplied with lamotrigine for peak identification CRS.<\/p>\n<p>Limit:<\/p>\n<p>\u2014 impurity E: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (c) (0.1 per cent).<\/p>\n<h4>Loss on drying (2.2.32)<\/h4>\n<p>Maximum 0.5 per cent, determined on 2.000 g by drying in an oven at 105 \u00b0C at a pressure not exceeding 0.7 kPa for 3 h.<\/p>\n<h4>Sulfated ash (2.4.14)<\/h4>\n<p>Maximum 0.1 per cent, determined on 2.0 g.<\/p>\n<h2>ASSAY<\/h2>\n<p>Dissolve 0.200 g in 60 mL of anhydrous acetic acid R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20). Carry out a blank titration.<\/p>\n<p>1 mL of 0.1 M perchloric acid is equivalent to 25.61 mg of C<sub>9<\/sub>H<sub>7<\/sub>Cl<sub>2<\/sub>N<sub>5<\/sub>.<\/p>\n<h2>IMPURITIES<\/h2>\n<p>Specified impurities A, E, F, G.<\/p>\n<p>Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) B, C, D.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16733\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-A-300x163.jpg\" alt=\"Lamotrigine\" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-A-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-A-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-A-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-A.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>A. 3-amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-5(4H)-one,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16734\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-B-300x163.jpg\" alt=\"Lamotrigine\" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-B-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-B-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-B-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-B.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>B. (2E)-[2-(diaminomethylidene)diazanylidene](2,3-dichlorophenyl)acetonitrile,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16735\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-C-300x163.jpg\" alt=\"Lamotrigine\" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-C-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-C-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-C-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-C.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>C. (2Z)-[2-(diaminomethylidene)diazanylidene](2,3-dichlorophenyl)acetonitrile,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16736\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-D-300x163.jpg\" alt=\"Lamotrigine\" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-D-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-D-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-D-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-D.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>D. 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5(2H,4H)-dione,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16737\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-E-300x163.jpg\" alt=\"Lamotrigine\" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-E-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-E-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-E-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-E.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>E. 2,3-dichlorobenzoic acid,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16738\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-F-300x163.jpg\" alt=\"Lamotrigine\" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-F-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-F-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-F-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-F.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>F. N-[5-amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-3-yl]-2,3-dichlorobenzamide,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16739\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-G-300x163.jpg\" alt=\"Lamotrigine\" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-G-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-G-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-G-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Lamotrigine-G.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>G. 6-(2,4-dichlorophenyl)-1,2,4-triazine-3,5-diamine.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Ph. Eur. monograph 1756) C9H7Cl2N5\u00a0 \u00a0 \u00a0 \u00a0256.1\u00a0 \u00a0 \u00a0 \u00a084057-84-1 Action and use Antiepileptic. Preparations Lamotrigine Dispersible Tablets Lamotrigine Tablets DEFINITION 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine. Content 99.0 per cent to 101.0 per cent (dried substance). CHARACTERS Appearance White or almost white powder. Solubility Very slightly soluble in water, slightly soluble in anhydrous ethanol. IDENTIFICATION Infrared absorption spectrophotometry&#8230;<\/p>\n","protected":false},"author":2,"featured_media":16740,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-16441","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/16441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=16441"}],"version-history":[{"count":3,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/16441\/revisions"}],"predecessor-version":[{"id":16741,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/16441\/revisions\/16741"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/16740"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=16441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=16441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=16441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}